U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07501156) titled 'H3K27M-specific Immune Effector Cells Targeting DMG/DIPG' on March 24.
Brief Summary: The purpose of this study is to assess the feasibility, safety and efficacy of H3K27M-specific engineered immune effector (EIE) therapy in patients with high-risk, H3K27M-positive diffuse midline glioma/diffuse intrinsic pontine glioma. Another goal of the study is to learn more about the function of the anti-H3K27M EIE cells and their persistency in patients.
Study Start Date: March 18
Study Type: INTERVENTIONAL
Condition:
Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Intervention:
BIOLOGICAL: H3K27M-EIEs
1 to 2 infusions, onc...